Invasive Skin Melanoma Terminated Phase 2 Trials for Regorafenib (DB08896)

IndicationStatusPhase
DBCOND0105239 (Invasive Skin Melanoma)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02587650Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV MelanomaTreatment